|
Accueil > Actualité
Biogen: acquires Reata Pharmaceuticals
(CercleFinance.com) - Biogen announces that it has entered into a definitive agreement with Reata Pharmaceuticals to acquire this biopharmaceutical company for $172.
50 per share in cash, reflecting an enterprise value of about $7.3bn. Specializing in therapies that regulate cellular metabolism and inflammation in severe neurological diseases, in particular Reata has Skyclarys, the only FDA-approved treatment for Friedreich's ataxia in the US. Biogen says that this acquisition represents a significant step forward in Biogen's sustainable growth strategy, with the addition of a highly complementary innovative product in an area where unmet medical needs are high. Copyright (c) 2023 CercleFinance.com. All rights reserved. |
16/05/2025 17:23
Walmarten vert après ses résultats, un broker à l'achat 16/05/2025 16:41 Merckva présenter ses avancées dans l'hypertension (HTAP) 16/05/2025 16:29 KKRaccord avec Inhabeo pour financer un campus étudiant 16/05/2025 15:55 UbisoftDWS Investment passe sous les 5% du capital 16/05/2025 15:00 Take-Twolourde perte sur des dépréciations au 4e trimestre 16/05/2025 14:41 Teslal'ancien directeur financier de Chipotle au conseil Tous les articles sociétés |
